Kai-Keen Shiu
@KaiKeenShiu
Followers
488
Following
550
Statuses
197
GI Medical Oncologist and Cancer of Unknown Primary Specialist @uclcancer, @uclh #cancerresearch #immunotherapy NEOPRISM-CRC Trial. All opinions my own.
London, England
Joined January 2023
Neoadjuvant immunotherapy all the way for dMMR/MSI-H CRC? 🙌 🙌#ASCO24 Lots of work still to be done for the benefit of our patients and the science 💉🧪🧬🔬🧐 Happy to be part of a team of research active oncologists @AndreaCercek @MyriamChalabi @KristenCiombor Join us! 🤝🤝
2
14
78
RT @ASCO: Now that #GI25 is over, catch up on all the news from the meeting with #ASCODailyNews. All coverage of the Symposium's top resear…
0
7
0
RT @CathyEngMD: Also pre dinner on the last day of #ASCO25 @asco I bumped into some of my fave people: @KaiKeenShiu @EvelynWongYT and @Deeb…
0
4
0
RT @KristenCiombor: Wells Messersmith giving a masterful discussion on (in my opinion) the most impactful data of #GI25
0
13
0
RT @CathyEngMD: Great discussion from Dr. Wells Messersmith @CUAnschutz on the impact of #BREAKWATER BRAF V600E MT tumor types, the DEEPER…
0
14
0
RT @SuyogCancer: Now that Nivo plus IPI has shown benift over single agent Nivolumab, what will u use in metastatic crc with MSI high , no…
0
6
0
RT @ArndtVogel: Nivolumab/ipilimumab versus nivolumab in MSI mCRC (CheckMate 8HW): a randomised, open-label, phase 3 trial 👇Get the full pa…
0
56
0
RT @dr_yakupergun: The New Standard of Care in MSI-H CRC: Nivolumab + Ipilimumab The CM-8HW trial has provided us with some important insi…
0
39
0
RT @ShaalanBeg: Now that the INTERIM results of the BREAKWATER trial have been presented #GI25, how will you treat newly diagnosed BREAF mu…
0
10
0
RT @Aiims1742: Straight from #GI25 in @NatureMedicine By @skopetz @CathyEngMD & colleagues Encorafenib, cetuximab and chemotherapy in BRA…
0
18
0
RT @ParseghianC: BREAKWATER Ph3 showing an incredible improvement in ORR by 21% and doubling of the duration of response with the addition…
0
7
0
RT @NiuSanford: ctDNA in CRC is prognostic, but there is no data showing that treatment initiated earlier based upon ctDNA positivity confe…
0
49
0
RT @KristenCiombor: Adding to our data of neoadjuvant pembro in MSI-H/dMMR colon cancer at CRC rapid abstracts -pCR rate of 44% after one d…
0
9
0
RT @GillSharlene: #GI25 @ASCO 🌟 Practice-changing ALASCCA ph3 trial 🇸🇪 📌 ASA 160mg in PIK3CA+ stage II-III #CRCsm 📌 PIK3CA+ in 37% ➡️ HR 0…
0
32
0
RT @EvelynWongYT: ALASCCA: Aspirin 1/2 Recurrence Risk in 3 yrs in PIK3CA-mt #CRC #cancer. PIK3CA Ex9/20: 7.7% vs 14.1% (HR 0.49, p=0.044)…
0
5
0
RT @ArndtVogel: Botensilimab with or without balstilimab in refractory MSS CRC with no liver metastases #ASCOGI25 🔎🗺️Phs-2 👉highest with 75…
0
20
0
RT @ShaalanBeg: Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic? Pan-RAS inhibitor shows early/deep molecular res…
0
40
0
RT @CathyEngMD: This is why I love being at in person meetings. Seeing old friends and discussing #science #cancer #cancer research. @Kai…
0
3
0
RT @SuyogCancer: Excellent table to show all the current data of CAR-T therapy in GI cancers. Note that median PFS is not more than 3 to 6…
0
15
0
RT @KeohaneNicola: Delighted to be able to showcase the results of our needs analysis study for Young Onset patients at GI ASCO #GI25
@Can…
0
12
0
RT @kevinjmonahan: Thank you to our @StMarksHospital familial colorectal cancer clinical research fellows #LynchSyndrome @curebowelcancer @…
0
11
0